Please login to the form below

Not currently logged in


This page shows the latest ABT-450 news and features for those working in and with pharma, biotech and healthcare.

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen. The US FDA has granted priority review to AbbVie's all-oral regimen for the treatment of adult patients ... The regimen consists of the protease inhibitor ABT-450 boosted by

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • Warehousing of HCV patients reaches new high

    However, Abbvie’s products ABT 267, ABT 333 and ABT 450 remain contenders for market share, scoring higher than J&J’s simeprevir in terms of likelihood to prescribe amongst doctors

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...